Primary Care Diabetes
Volume 1, Issue 2 , Pages 99-101 , June 2007

HIV and diabetes

Received 10 April 2007 ,Accepted 10 April 2007.

References 

  1. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with HIV infection and lipodystrophy. Clin. Infect. Dis. 2001;32:130–139
  2. Y.P. Samarasinghe, C. Higgs, B. Gazzard, M.D. Feher, Diabetes in a HIV population: a hidden epidemic, Diab. Med. 19 (Suppl. 2) (2002) 28–115, P66.
  3. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicentre AIDS cohort study. Arch. Int. Med. 2005;165:1179–1184
  4. Brown TT, Li X, Cole SR, Kingsley LA, Lawrence A, Palella FJ, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19(13):1375–1383
  5. Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. JAIDS. 2005;39(5):557–561
  6. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13(10):F63–F70
  7. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, et al. Metabolic effects of indinivir in healthy HIV-seronegative men. AIDS. 2001;15(7):F11–F18
  8. Noor MA, Parker RA, O’Mara E, Grasela DM, Currie A, Hodder SL, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137–2144
  9. Jones SP, Janeh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir. Ther. 2005;10(2):207–213
  10. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 2003;349(21):1993–2003
  11. Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. Am. J. Med. 2005;108(Suppl. 2):3S–8S
  12. Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, d’Arminio Monforte A, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with the observed events in the D:A:D Study. HIV Med. 2006;7(4):218–230
  13. JBS 2: Joint British Societies’ Guidelines on Prevention of Cardiovascular Disease in Clinical Practice, Heart 91 (Suppl. V) (2005) v1–v52.

PII: S1751-9918(07)00038-1

doi: 10.1016/j.pcd.2007.04.001

Primary Care Diabetes
Volume 1, Issue 2 , Pages 99-101 , June 2007

Article Tools